Radioiodine News and Research

RSS

Iodine-131 (131I), also called radioiodine (though many other radioactive isotopes of this element are known), is an important radioisotope of iodine. It has a radioactive decay half life of about eight days. Its uses are mostly medical and pharmaceutical.

New guidance on radioiodine therapy use after radiographic studies

Researchers have provided new evidence that could act as a guide for the use of radioiodine therapy after patients have undergone radiographic imaging studies that use iodine as a contrasting agent.

30 Apr 2013

First combination treatment of microwave ablation, radiotherapy performed on 52-year-old patient

Dr. Hudayi Korkusuz, a radiologist at the Department of Nuclear Medicine, has conducted the first combination treatment of microwave ablation and radiotherapy.

10 Apr 2013

Genzyme receives EC approval for Thyrogen product label expansion

Genzyme, a Sanofi company, today announced it has received European Commission approval of a product label expansion for the use of Thyrogen (thyrotropin alfa) with a wider irradiation dose range for postoperative thyroid remnant ablation.

10 Dec 2012

New York State Department of Health issues license to Veracyte's Afirma Gene Expression Classifier

Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, and Genzyme, a Sanofi company, today announced that the New York State Department of Health has issued a license enabling Veracyte's Afirma Gene Expression Classifier to be offered to patients in the state.

30 Aug 2012

Vandetanib shows efficacy in thyroid cancer

The tyrosine kinase inhibitor vandetanib could significantly extend progression-free survival in patients with locally advanced or metastatic differentiated radioiodine-refractory thyroid cancer, show results of a small phase II randomized trial.

24 Aug 2012

First detailed analysis of Fukushima Daiichi nuclear disaster's global health effects

Radiation from Japan's Fukushima Daiichi nuclear disaster may eventually cause anywhere from 15 to 1,300 deaths and from 24 to 2,500 cases of cancer, mostly in Japan, Stanford researchers have calculated.

18 Jul 2012

SPECT/CT can change clinical management of thyroid cancer

The use of single positron emission computed tomography (SPECT)/computed tomography (CT) has been reported to change clinical management in a significant number of thyroid cancer patients according to research presented in the May issue of The Journal of Nuclear Medicine.

4 May 2012

HiLo trial sets new gold standard for thyroid cancer treatment

The results of a large Cancer Research UK trial have set a new gold standard for treating thyroid cancer, reducing radiation doses to just one third of the current level, according to research in The New England Journal of Medicine.

3 May 2012

New way to exploit expression of BRAF by papillary carcinomas for therapeutic purposes

Papillary carcinoma is the most common form of thyroid cancer. Approximately one quarter of these carcinomas have mutations in the BRAF gene. The prevalence of such mutations is even greater in high-grade carcinomas, particularly those that are refractory to standard treatment, which is radioactive iodine.

22 Nov 2011

Glitazone treatment does not cause side effects in patients with metastatic thyroid cancer

Repeated radio-ablation therapy with iodine-131 to treat metastatic thyroid cancer can be less effective than the initial round of treatment due to de-differentiation of the cancer cells as the disease progresses, making them less sensitive to I-131.

29 Oct 2011

Researchers explore novel therapeutic approach for thyroid cancer

Some forms of differentiated thyroid cancer (DTC) respond to treatment with radioactive iodine, which is taken up by the thyroid gland, destroying the cancerous cells. However patients with two forms of thyroid cancer, radioiodine-refractory DTC and anaplastic thyroid cancer (ATC), do not benefit from radioiodine therapy, and other treatment options are limited.

28 Oct 2011

Lenvatinib may achieve partial response in thyroid, endometrial, and renal cancers

Phase 1 clinical studies of the experimental anticancer drug lenvatinib indicate that it may achieve at least a partial response in thyroid, endometrial, and renal cancers and melanoma.

28 Oct 2011

ATA announces five recipients of 2011 thyroid cancer research grants

The American Thyroid Association (ATA) announced the five recipients of its 2011 research grants, each of whom will receive up to $25,000 annually for up to two years. Three of the five recipients were awarded special ATA ThyCa grants for research projects that focus on thyroid cancer. These grants are funded by ThyCa: Thyroid Cancer Survivors, Inc.

8 Sep 2011

Radioiodine being overused in thyroid cancer: Study

According to the latest research the use of radioactive iodine to treat thyroid cancer increased 40 percent from 1990 to 2008 even though the risks may outweigh the benefits for some patients, particularly those with early-stage tumors.

17 Aug 2011

New method uses ICP-MS system to identify radioactive elements in environment

Agilent Technologies Inc. today announced it has developed a new method to identify radioactive iodine using inductively coupled plasma mass spectrometry (ICP-MS). The method will first be used by Gakushuin University in Japan, with a donated Agilent 7700 ICP-MS System.

15 Jun 2011

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Preliminary results of a Phase II single-arm study to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's lenvatinib demonstrated an Objective Response Rate of 59% (34/58, 95% CI: 45-71), based on an updated investigator assessment, in patients with advanced radioiodine (RAI)-refractory differentiated thyroid cancer.

1 Jun 2011

Research on rare cancers

A cancer diagnosis can be a life-changing event. Many questions arise, with one of the first being, "Where should I be treated?" Patients diagnosed with rare cancers may have difficulty finding a physician knowledgeable in treating their type of cancer.

11 Apr 2011